Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade

Benci, Joseph L., Xu, Bihui, Qiu, Yu, Wu, Tony J., Dada, Hannah, Twyman-Saint Victor, Christina, Cucolo, Lisa, Lee, David S.M., Pauken, Kristen E., Huang, Alexander C., Gangadhar, Tara C., Amaravadi, Ravi K., Schuchter, Lynn M., Feldman, Michael D., Ishwaran, Hemant, Vonderheide, Robert H., Maity, Amit, Wherry, E. John, Minn, Andy J.·2016·Cell
DOI 10.1016/j.cell.2016.11.022

Cited by (1,000)

Items 401–500 of 1,000

  1. Targeting the TRIM14/USP14 Axis Enhances Immunotherapy Efficacy by Inducing Autophagic Degradation of PD-L1
    Di Liu, Mengqiu Li, Zhiyao Zhao, Liang Zhou, Feng Zhi, Zhiyong Guo, Jun Cui · 2024 · Cancer Research
  2. Radiation as an immune modulator: mechanisms and implications for combination with immunotherapy
    Laurel B. Darragh, Sana D. Karam · 2026 · Nature reviews. Cancer
  3. Targeting Histone Deacetylase 6 Reprograms Interleukin‐17‐Producing Helper T Cell Pathogenicity and Facilitates Immunotherapies for Hepatocellular Carcinoma
    Weinan Qiu, Bin Wang, Yanan Gao, Yuan Tian, Meijie Tian, Yuanying Chen, Li ming Xu, Tso‐Pang Yao, Peng Li, Pengyuan Yang · 2019 · Hepatology
  4. The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer
    Shuling Zhang, Xueli Bai, Fengping Shan · 2020 · International Immunopharmacology
  5. An Immunomodulatory Gallotanin-Rich Fraction From Caesalpinia spinosa Enhances the Therapeutic Effect of Anti-PD-L1 in Melanoma
    Paola Lasso, Alejandra Gomez‐Cadena, Claudia Patricia Urueña, Alena Donda, Amaia Martínez-Usatorre, Pedro J. Romero, Alfonso Barreto, Susana Fiorentino G · 2020 · Frontiers in Immunology
  6. FAM120A couples SREBP-dependent transcription and splicing of lipogenesis enzymes downstream of mTORC1
    Sungyun Cho, Yujin Chun, Long He, Cuauhtemoc B. Ramirez, Kripa S. Ganesh, Kyungjo Jeong, Junho Song, Jin‐Gyu Cheong, Zhongchi Li, Jungmin Choi et al. · 2023 · Molecular Cell
  7. Immune checkpoints and cancer immunotherapies: insights into newly potential receptors and ligands
    Ali Naghi Kamali, José Manuel Bautista, Michael Eisenhut, Haleh Hamedifar · 2023 · Therapeutic Advances in Vaccines and Immunotherapy
  8. Conserved immuno‐collagenic subtypes predict response to immune checkpoint blockade
    Jie Mei, Yun Cai, Rui Xu, Qing Li, Jiahui Chu, Zhiwen Luo, Yaying Sun, Yuxin Shi, Junying Xu, Di Li et al. · 2024 · 癌症：英文版
  9. Cytokine-armed pyroptosis induces antitumor immunity against diverse types of tumors
    Sara Orehek, Taja Železnik Ramuta, Duško Lainšček, Špela Malenšek, Martin Šala, Mojca Benčina, Roman Jerala, Iva Hafner‐Bratkovič · 2024 · Nature Communications
  10. Type I Interferon Delivery by iPSC-Derived Myeloid Cells Elicits Antitumor Immunity via XCR1+ Dendritic Cells
    Nobuhiro Tsuchiya, Rong Zhang, Tatsuaki Iwama, Norihiro Ueda, Tianyi Liu, Minako Tatsumi, Yutaka Sasaki, Ranmaru Shimoda, Yuki Osako, Yu Sawada et al. · 2019 · Cell Reports
  11. A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC
    Marzia Del Re, Federico Cucchiara, Eleonora Rofi, Lorenzo Fontanelli, Iacopo Petrini, Nicole Gri, Giulia Pasquini, Mimma Rizzo, Michela Gabelloni, Lorenzo Belluomini et al. · 2020 · Cancer Immunology Immunotherapy
  12. Galectin-9 blockade synergizes with ATM inhibition to induce potent anti-tumor immunity
    Shuang Zheng, Jiaming Song, Dongli Linghu, Ri‐Yao Yang, Boning Liu, Zhen Xue, Qihui Chen, Chengjie Liu, Diansheng Zhong, Mien‐Chie Hung et al. · 2023 · International Journal of Biological Sciences
  13. The spread of interferon-γ in melanomas is highly spatially confined, driving nongenetic variability in tumor cells
    Edoardo Centofanti, Chad Wang, Sandhya Iyer, Oleg Krichevsky, Alon Oyler‐Yaniv, Jennifer E. Oyler · 2023 · Proceedings of the National Academy of Sciences
  14. Signaling by Type I Interferons in Immune Cells: Disease Consequences
    Μαρκέλλα Ζαννίκου, Eleanor N. Fish, Leonidas C. Platanias · 2024 · Cancers
  15. Interferon Signaling Is Frequently Downregulated in Melanoma
    Sara Alavi, Ashleigh Stewart, Richard F. Kefford, Su Yin Lim, Elena Shklovskaya, Helen Rizos · 2018 · Frontiers in Immunology
  16. Multiple tumor suppressors regulate a HIF-dependent negative feedback loop via ISGF3 in human clear cell renal cancer
    Lili Liao, Zongzhi Z. Liu, Lauren E. Langbein, Weijia Cai, Eun-Ah Cho, Jie Na, Xiaohua Niu, Wei Jiang, Zhijiu Zhong, Wesley L. Cai et al. · 2018 · eLife
  17. Expanded human NK cells from lung cancer patients sensitize patients’ PDL1−negative tumors to PD1-blockade therapy
    Sophie M. Poznanski, Tyrah M. Ritchie, Isabella Y. Fan, Abdullah El‐Sayes, Ana L. Portillo, Ronny Ben-Avi, Eduardo A. Peña Rojas, Marianne V. Chew, Yaron Shargall, Ali A. Ashkar · 2021 · Journal for ImmunoTherapy of Cancer
  18. GATA4 controls regionalization of tissue immunity and commensal-driven immunopathology
    Zachary M. Earley, Wioletta Lisicka, Joseph J. Sifakis, Raúl Aguirre‐Gamboa, Anita Kowalczyk, Jacob T. Barlow, Dustin G. Shaw, Valentina Discepolo, Ineke L. Tan, Saideep Gona et al. · 2023 · Immunity
  19. Epigenetic mechanisms of tumor resistance to immunotherapy
    Arenas-Ramirez, Natalia, Sahin, Dilara, Boyman, Onur · 2018 · Cellular and Molecular Life Sciences
  20. Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy
    Elodie Lauret Marie Joseph, Amos Kirilovsky, Benoît Lecoester, Carine El Sissy, Laura Boullerot, Laurie Rangan, Amélie Marguier, Florent Tochet, Magalie Dosset, Jihane Boustani et al. · 2021 · Journal for ImmunoTherapy of Cancer
  21. Cancer Resistance to Immunotherapy: Molecular Mechanisms and Tackling Strategies
    Son Hai Vu, Preethi Vetrivel, Jongmin Kim, Myeong‐Sok Lee · 2022 · International Journal of Molecular Sciences
  22. NAD + depletion by type I interferon signaling sensitizes pancreatic cancer cells to NAMPT inhibition
    Alexandra M. Moore, Lei Zhou, Jing Cui, Luyi Li, Nanping Wu, Alice C. Yu, Soumya Poddar, Keke Liang, Evan R. Abt, Stephanie Kim et al. · 2021 · Proceedings of the National Academy of Sciences
  23. Hepatic interferon regulatory factor 8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti–programmed cell death protein‐1 therapy
    Hongxi Wu, Li Yan, Guangjiang Shi, Shijia Du, Xiaobin Wang, Wanli Ye, Zixuan Zhang, Ya Chu, Shuqian Ma, Dajia Wang et al. · 2022 · Hepatology
  24. Transforming the prostatic tumor microenvironment with oncolytic virotherapy
    Matthew J. Atherton, Kyle B. Stephenson, Fanny Tzelepis, David Bakhshinyan, Jake K. Nikota, Hwan Hee Son, Anna Jirovec, Charles A. Lefebvre, Anna Dvorkin‐Gheva, Ali A. Ashkar et al. · 2018 · OncoImmunology
  25. Activating the Nucleic Acid-Sensing Machinery for Anticancer Immunity
    Terry R. Medler, Jaina M. Patel, Alejandro F. Alice, Jason R. Baird, Hong‐Ming Hu, Michael J. Gough · 2018 · International review of cytology
  26. Intracellular RNA Sensing in Mammalian Cells: Role in Stress Response and Cancer Therapies
    Nikolai N. Khodarev · 2018 · International review of cytology
  27. Dissecting the Immune Landscape of Acute Myeloid Leukemia
    Jan Kenneth Davidson-Moncada, Elena Viboch, SE Church, Sarah E. Warren, Sergio Rutella · 2018 · Biomedicines
  28. Head and Neck Cancers Promote an Inflammatory Transcriptome through Coactivation of Classic and Alternative NF-κB Pathways
    Xinping Yang, Hui Wen Cheng, Jianhong Chen, Ru Wang, Anthony D. Saleh, Han Si, Steven S. Lee, Emine Guven‐Maiorov, Özlem Keskin, Attila Gürsoy et al. · 2019 · Cancer Immunology Research
  29. Role of tumor microenvironment in the regulation of PD‐L1: A novel role in resistance to cancer immunotherapy
    Nirvana Kalantari Khandani, Atefeh Ghahremanloo, Seyed Isaac Hashemy · 2020 · Journal of Cellular Physiology
  30. A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma
    Weinan Guo, Jinyuan Ma, Sen Guo, Huina Wang, Sijia Wang, Qiong Shi, Lin Liu, Tao Zhao, Fengfan Yang, Shuyang Chen et al. · 2020 · Journal for ImmunoTherapy of Cancer
  31. Immunotherapy Resistance in Glioblastoma
    Wang, Elaina J., Chen, Jia-Shu, Jain, Saket, Morshed, Ramin A., Haddad, Alexander F., Gill, Sabraj, Beniwal, Angad S., Aghi, Manish K. · 2021 · Frontiers in Genetics
  32. An iron-rich subset of macrophages promotes tumor growth through a Bach1-Ednrb axis
    Ian Wesley Folkert, William A. Molina Arocho, Tsun Ki Jerrick To, Samir Devalaraja, Irene S. Molina, Jason Shoush, Hesham Mohei, Li Zhai, Md. Naushad Akhtar, Veena Kochat et al. · 2024 · The Journal of Experimental Medicine
  33. Co-evolution of glioma and immune microenvironment
    Mahmoud M. Elguindy, Jacob S. Young, Winson S. Ho, Rongze O. Lu · 2024 · Journal for ImmunoTherapy of Cancer
  34. Interferon signaling pathways in health and disease
    Chunli Wen, Qingzhan Lan, Yunshan Wang, Yang Ni, Alice S.T. Wong, Duanrui Liu · 2025 · Molecular Biomedicine
  35. Predictive factors of response to immunotherapy—a review from the Spanish Melanoma Group (GEM)
    On behalf of the Spanish Melanoma Group (GEM), Enrique Espinosa, Iván Márquez‐Rodas, Ainara Soria, Alfonso Berrocal, José Luís Manzano, María González‐Cao, Salvador Martín‐Algarra · 2017 · Annals of Translational Medicine
  36. The role of T-cell immunoglobulin mucin-3 and its ligand galectin-9 in antitumor immunity and cancer immunotherapy
    Ri‐Yao Yang, Mien‐Chie Hung · 2017 · Science China Life Sciences
  37. PD-1/PD-L1 counterattack alliance: multiple strategies for treating triple-negative breast cancer
    Haiying Zhu, Chengyong Du, Meng Yuan, Peifen Fu, Qiaojun He, Bo Yang, Ji Cao · 2020 · Drug Discovery Today
  38. Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer
    Wei Liu, Lei Zhang, Zhiming Xiu, Jian Guo, Liye Wang, Yue Zhou, Yang Jiao, Meiyan Sun, Jianhui Cai · 2020 · OncoTargets and Therapy
  39. Interferon Signaling in Estrogen Receptor–positive Breast Cancer: A Revitalized Topic
    Xiaoyong Fu, Carmine De Angelis, Rachel Schiff · 2021 · Endocrinology
  40. Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
    Carlo Genova, Roberta Tasso, Alessandra Rosa, Giovanni Rossi, Daniele Reverberi, Vincenzo Fontana, Silvia Marconi, Michela Croce, Maria Giovanna Dal Bello, Chiara Dellepiane et al. · 2023 · Cells
  41. Immune Resistance Mechanisms and the Road to Personalized Immunotherapy
    Miles Piper, Harriet M. Kluger, Eytan Ruppin, Siwen Hu‐Lieskovan · 2023 · American Society of Clinical Oncology Educational Book
  42. Targeting TCF19 sensitizes MSI endometrial cancer to anti-PD-1 therapy by alleviating CD8+ T cell exhaustion via TRIM14-IFN-β axis
    Xinyue Ma, Qiuman Wang, Chenggong Sun, Indu Agarwal, Huan Wu, Jingying Chen, Chen Zhao, Gonghua Qi, Qiuli Teng, Cunzhong Yuan et al. · 2023 · Cell Reports
  43. Sustained Type I Interferon Reinforces NK Cell–Mediated Cancer Immunosurveillance during Chronic Virus Infection
    Ji Hoon Oh, Myeong Joon Kim, Seong Jin Choi, Young Ho Ban, Heung Kyu Lee, Eui‐Cheol Shin, Kyung-Mi Lee, Sang‐Jun Ha · 2019 · Cancer Immunology Research
  44. LNK suppresses interferon signaling in melanoma
    Ling‐Wen Ding, Qiao‐Yang Sun, Jarem J. Edwards, Lucia Torres Fernández, Xue‐Bin Ran, Siqin Zhou, Richard A. Scolyer, James S. Wilmott, John F. Thompson, Ngan Doan et al. · 2019 · Nature Communications
  45. Immunoradiotherapy as an Effective Therapeutic Strategy in Lung Cancer: From Palliative Care to Curative Intent
    Rodolfo Chicas-Sett, Juan Zafra, Ignacio Morales-Orue, Juan Castilla-Martinez, Miguel Ángel Berenguer Francés, Elisa González-Rodríguez, Delvys Rodríguez‐Abreu, Felipe Couñago · 2020 · Cancers
  46. Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer
    Samia S. Messeha, Najla O. Zarmouh, Karam F. A. Soliman · 2021 · Nutrients
  47. Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy
    Miles Cameron Andrews, Alexandre Reuben, Vancheswaran Gopalakrishnan, Jennifer Ann Wargo · 2018 · Frontiers in Immunology
  48. A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors
    Matthew R. Zibelman, Alexander W. Macfarlane, Kimberly Costello, Thomas McGowan, John O’Neill, Rutika A Kokate, Hossein Borghaei, Crystal Shereen Denlinger, Efrat Dotan, Daniel M. Geynisman et al. · 2023 · Nature Communications
  49. Exosomal PD-L1 in cancer and other fields: recent advances and perspectives
    Manman Lu, Yu Yang · 2024 · Frontiers in Immunology
  50. The paradoxical role of IFN-γ in cancer: Balancing immune activation and immune evasion
    Xiaojuan Liu · 2025 · Pathology - Research and Practice
  51. Sensitization of tumours to immunotherapy by boosting early type-I interferon responses enables epitope spreading
    Sadeem Qdaisat, Brandon M. Wummer, Brian D. Stover, Dingpeng Zhang, James McGuiness, Frances L. Weidert, Jonathan Chardon‐Robles, Adam Grippin, Anna DeVries, Chong Zhao et al. · 2025 · Nature Biomedical Engineering
  52. A TLR7 agonist strengthens T and NK cell function during BRAF‐targeted therapy in a preclinical melanoma model
    Lydia Bellmann, Giuseppe Cappellano, Johanna F. Schachtl‐Riess, Natasa Prokopi, Athanasios Seretis, Daniela Ortner, Christoph H. Tripp, Constance Brinckerhoff, David W. Mullins, Patrizia Stoitzner · 2019 · International Journal of Cancer
  53. Effects of oncolytic viruses and viral vectors on immunity in glioblastoma
    Penghao Liu, Yaning Wang, Yuekun Wang, Ziren Kong, Wenlin Chen, Jiatong Li, Wenlin Chen, Yu Wang, Wenbin Ma, Yu Wang · 2020 · Gene Therapy
  54. Context Is Key: Delineating the Unique Functions of IFNα and IFNβ in Disease
    Lindsey E. Fox, Marissa C. Locke, Deborah J. Lenschow · 2020 · Frontiers in Immunology
  55. Intrinsic Interferon Signaling Regulates the Cell Death and Mesenchymal Phenotype of Glioblastoma Stem Cells
    Sabbir Khan, Rajasekaran Mahalingam, Shayak Sen, Emmanuel Martínez-Ledesma, Arshad Khan, Kaitlin Gandy, Frederick F. Lang, Erik P. Sulman, Kristin D. Alfaro-Munoz, Nazanin Majd et al. · 2021 · Cancers
  56. H2AFZ Is a Prognostic Biomarker Correlated to TP53 Mutation and Immune Infiltration in Hepatocellular Carcinoma
    Mingwei Dong, Jing Chen, Yiran Deng, Danying Zhang, Ling Dong, Dalong Sun · 2021 · Frontiers in Oncology
  57. Central Role of the Antigen-Presentation and Interferon-γ Pathways in Resistance to Immune Checkpoint Blockade
    Annette Paschen, Ignacio Melero, Antoni Ribas · 2021 · Annual Review of Cancer Biology
  58. Laser immunotherapy for cutaneous squamous cell carcinoma with optimal thermal effects to enhance tumour immunogenicity
    Min Hua Luo, Lei Shi, Fuhe Zhang, Feifan Zhou, Linglin Zhang, Bo Wang, Peiru Wang, Yunfeng Zhang, Haiyan Zhang, Degang Yang et al. · 2018 · International Journal of Hyperthermia
  59. Systematic Interrogation of Tumor Cell Resistance to Chimeric Antigen Receptor T-cell Therapy in Pancreatic Cancer
    Kimberly R. Hagel, Rand Arafeh, Sydney Gang, Taylor E. Arnoff, Rebecca C. Larson, John G. Doench, Nathan D. Mathewson, Kai W. Wucherpfennig, Marcela Valderrama Maus, William C. Hahn · 2022 · Cancer Research
  60. Smart drug delivery systems to overcome drug resistance in cancer immunotherapy
    Wenzhe Yi, Dan Yan, Dangge Wang, Yaping Li · 2023 · Cancer Biology and Medicine
  61. The role of IFN-γ-signalling in response to immune checkpoint blockade therapy
    Chun Wai Wong, Yang Huang, Adam F. L. Hurlstone · 2023 · Essays in Biochemistry
  62. Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening
    Azucena Ramos, Catherine E. Koch, Yunpeng Liu-Lupo, Riley D. Hellinger, Taeyoon Kyung, Keene L. Abbott, Julia Fröse, Daniel R. Goulet, Khloe S. Gordon, Keith P. Eidell et al. · 2023 · Nature Communications
  63. Immunosurveillance encounters cancer metabolism
    Yu‐Ming Chuang, Sheue‐Fen Tzeng, Ping‐Chih Ho, Chin‐Hsien Tsai · 2024 · EMBO Reports
  64. YTHDF1 loss in dendritic cells potentiates radiation-induced antitumor immunity via STING-dependent type I IFN production
    Chuangyu Wen, Liangliang Wang, András Piffkó, Dapeng Chen, Xianbin Yu, Katarzyna Zawieracz, Jason Bugno, Kaiting Yang, Emile Z. Naccasha, Fei Ji et al. · 2024 · Journal of Clinical Investigation
  65. Nucleo-cytosolic acetyl-CoA drives tumor immune evasion by regulating PD-L1 in melanoma
    Huina Wang, Xiuli Yi, Xiangxu Wang, Yuqi Yang, Hengxiang Zhang, Hao Wang, Jianru Chen, Baolu Zhang, Sen Guo, Lili Wu et al. · 2024 · Cell Reports
  66. PSAT1 impairs ferroptosis and reduces immunotherapy efficacy via GPX4 hydroxylation
    Peixiang Zheng, Zhiqiang Hu, Yuli Shen, Lina Gu, Yuan Ouyang, Yuran Duan, Guimei Ji, Bofei Dong, Yanni Lin, Ting Wen et al. · 2025 · Nature Chemical Biology
  67. Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma
    Nicolas Jacquelot, Jonathan M. Pitt, David Pierre Enot, María Paula Roberti, Connie P.M. Duong, Sylvie Rusakiewicz, Alexander M.M. Eggermont, Laurence Zitvogel · 2017 · OncoImmunology
  68. 5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy
    Cappuccini, Federica, Pollock, Emily, Stribbling, Stephen, Hill, Adrian V.S., Redchenko, Irina · 2017 · Oncotarget
  69. Myeloid-Derived Suppressive Cell Expansion Promotes Melanoma Growth and Autoimmunity by Inhibiting CD40/IL27 Regulation in Macrophages
    Julio C. Valencia, Rebecca A. Erwin-Cohen, Paúl E. Clavijo, Clint Allen, Michael E. Sanford, Chi-Ping Day, Megan M. Hess, Morgan Johnson, Jie Yin, John M. Fenimore et al. · 2021 · Cancer Research
  70. DNA methylation regulates TIGIT expression within the melanoma microenvironment, is prognostic for overall survival, and predicts progression-free survival in patients treated with anti-PD-1 immunotherapy
    Dennis Niebel, Anne Fröhlich, Romina Zarbl, Simon Fietz, Luka de Vos, Timo Jakob Vogt, Jörn Dietrich, Judith D. Sirokay, Pia Kuster, Gonzalo Saavedra et al. · 2022 · Clinical Epigenetics
  71. Alum-anchored intratumoral retention improves the tolerability and antitumor efficacy of type I interferon therapies
    Emi A. Lutz, Yash Agarwal, Noor Momin, Sarah C. Cowles, Joseph R. Palmeri, Ellen Duong, Vladlena Hornet, Allison M. Sheen, Brianna M. Lax, Adrienne M. Rothschilds et al. · 2022 · Proceedings of the National Academy of Sciences
  72. SP140 inhibits STAT1 signaling, induces IFN-γ in tumor-associated macrophages, and is a predictive biomarker of immunotherapy response
    Kranthi Kiran Kishore Tanagala, Joshua Morin‐Baxter, Richard D. Carvajal, Maryum Cheema, Sunil Dubey, Hiroshi Nakagawa, Angela J. Yoon, Yi‐Shing Lisa Cheng, Alison Marie Taylor, Jeffrey A. Nickerson et al. · 2022 · Journal for ImmunoTherapy of Cancer
  73. Aerosolized immunotherapeutic nanoparticle inhalation potentiates PD-L1 blockade for locally advanced lung cancer
    Yang Liu, William N. Crowe, Lulu Wang, William Jeffrey Petty, Amyn A. Habib, Dawen Zhao · 2022 · Nano Research
  74. Mechanisms regulating immune surveillance of cellular stress in cancer
    Ruth Seelige, Stephen C. Searles, Jack D. Bui · 2017 · Cellular and Molecular Life Sciences
  75. Mechanisms of Resistance to Anti-PD-1 Immunotherapy in Melanoma and Strategies to Overcome It
    Magdalena K. Zielińska, Magdalena A. Ciążyńska, Dorota Sulejczak, Piotr Lukasz Rutkowski, Anna Malgorzata Czarnecka · 2025 · Biomolecules
  76. Inhibition of tumor-intrinsic NAT10 enhances antitumor immunity by triggering type I interferon response via MYC/CDK2/DNMT1 pathway
    Wan-cheng Liu, Yihong Wei, Jinfeng Chen, Xiangling Xing, Hexiao Jia, Xinyu Yang, Yingjian Huang, Xiao-min Liu, Ke Xiao, Xiaodong Guo et al. · 2025 · Nature Communications
  77. Overview of Interferon: Characteristics, signaling and anti-cancer effect
    Huaiyuan Wang, Haijun Hu, Kangjian Zhang · 2017 · Archives of Biotechnology and Biomedicine
  78. PARP1 depletion induces RIG-I-dependent signaling in human cancer cells
    Rajib Ghosh, Sanchita Roy, Sonia Franco · 2018 · PLoS ONE
  79. The DNA damage response in immunotherapy and radiation
    Robert M. Samstein, Nadeem Riaz · 2018 · Advances in Radiation Oncology
  80. Clonal tracing reveals diverse patterns of response to immune checkpoint blockade
    Shengqing Stan Gu, Xiaoqing Wang, Xihao Sherlock Hu, Peng Jiang, Ziyi Li, Nicole C. Traugh, Xia Bu, Qin Tang, Chenfei Wang, Zexian Zeng et al. · 2020 · Genome biology
  81. Constitutive and acquired mechanisms of resistance to immune checkpoint blockade in human cancer
    Matteo Bellone, Angela Rita Elia · 2017 · Cytokine & Growth Factor Reviews
  82. Preclinical development and clinical studies of targeted JAK/STAT combined Anti-PD-1/PD-L1 therapy
    Miaomiao Chen, Si-Liang Wang · 2024 · International Immunopharmacology
  83. IFN-γ and CD38 in Hyperprogressive Cancer Development
    Stefania Angelicola, Francesca Ruzzi, Lorena Landuzzi, Laura Scalambra, Francesco Gelsomino, Andrea Ardizzoni, Patrizia Nanni, Pier‐Luigi Lollini, Arianna Palladini · 2021 · Cancers
  84. TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer
    Teng Li, Han Wang, Jiachen Xu, Chengcheng Li, Yudong Zhang, Guoqiang Wang, Yutao Liu, Shangli Cai, Wenfeng Fang, Junling Li et al. · 2021 · Therapeutic Advances in Medical Oncology
  85. Bridging Radiotherapy to Immunotherapy: The IFN–JAK–STAT Axis
    Lewis Z. Shi, James A. Bonner · 2021 · International Journal of Molecular Sciences
  86. Mutant p53 gain of function mediates cancer immune escape that is counteracted by APR-246
    Xiaolei Zhou, Gema Sanz, Yue Zhan, Mariana M. S. Oliveira, Shiva Rezaei, Madhurendra Singh, Sylvain Peuget, Lisa S. Westerberg, John Inge Johnsen, Galina Selivanova · 2022 · British Journal of Cancer
  87. Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors
    Yingming Zhu, Fen Zhao, Zhenxiang Li, Jinming Yu · 2018 · Cancer Management and Research
  88. Pomalidomide Inhibits PD-L1 Induction to Promote Antitumor Immunity
    Yuki Fujiwara, Yi Sun, Robert J. Torphy, Jiadai He, Katsuhiko K. Yanaga, Barish H. Edil, Richard David Schulick, Yuwen Zhu · 2018 · Cancer Research
  89. TRAIL receptor-induced features of epithelial-to-mesenchymal transition increase tumour phenotypic heterogeneity: potential cell survival mechanisms
    Ludovic Peyre, Mickaël Meyer, Paul M Hofman, Jérémie Roux · 2020 · British Journal of Cancer
  90. Metabolic adaptations determine whether natural killer cells fail or thrive within the tumor microenvironment
    Adnan Moinuddin, Sophie M. Poznanski, Ana L. Portillo, Jonathan K. Monteiro, Ali A. Ashkar · 2024 · Immunological Reviews
  91. Further knowledge and developments in resistance mechanisms to immune checkpoint inhibitors
    Léa Berland, Zeina Gabr, Michelle Chang, Marius Ilié, Véronique Hofman, Guylène Rignol, François Ghiringhelli, Baharia Mograbi, Mohamad Rashidian, Paul M Hofman · 2024 · Frontiers in Immunology
  92. Humoral determinants of checkpoint immunotherapy
    Yile Dai, Lilach Aizenbud, Kai Qin, Matthew R Austin, Jillian R. Jaycox, Joseph Cunningham, Eric Y. Wang, Lin Zhang, Suzanne Fischer, Sean M. Carroll et al. · 2025 · Nature
  93. CAR T-cell therapy in highly aggressive B-cell lymphoma: emerging biological and clinical insights
    Alaa Mohammed Ali, Andre Henri Goy, Kieron M. Dunleavy · 2022 · Blood
  94. Selective suppression of melanoma lacking IFN-γ pathway by JAK inhibition depends on T cells and host TNF signaling
    Hongxing Shen, Fengyuan Huang, Xiangmin Zhang, Oluwagbemiga A. Ojo, Yuebin Li, Hoa Quang Trummell, Joshua Charles Anderson, John B. Fiveash, Markus Bredel, Eddy Shih-Hsin Yang et al. · 2022 · Nature Communications
  95. IFNγ is a central node of cancer immune equilibrium
    Michael J. Walsh, Courtney T. Stump, Rakeeb Kureshi, Patrick J. Lenehan, Lestat R. Ali, Michael Lawrence Dougan, David M. Knipe, Stephanie K. Dougan · 2023 · Cell Reports
  96. Candidate immune biomarkers for radioimmunotherapy
    Antonin Lévy, Giulia Nigro, Philippe Jean Sansonetti, Éric Deutsch · 2017 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  97. Functional and spatial proteomics profiling reveals intra- and intercellular signaling crosstalk in colorectal cancer
    Plattner, Christina, Lamberti, Giorgia, Blattmann, Peter, Kirchmair, Alexander, Rieder, Dietmar, Loncova, Zuzana, Sturm, Gregor, Scheidl, Stefan, Ijsselsteijn, Marieke, Fotakis, Georgios et al. · 2023 · iScience
  98. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Strategies and Biomarkers Predicting Response and/or Resistance
    Filippo Pelizzaro, Fabio Farinati, Franco Trevisani · 2023 · Biomedicines
  99. TGFβ Antagonizes IFNγ-Mediated Adaptive Immune Evasion via Activation of the AKT–Smad3–SHP1 Axis in Lung Adenocarcinoma
    Fan Ye, Zihao Cai, Boyu Wang, Chenxi Zeng, Yu Xi, Shaojie Hu, Rirong Qu, Zhiwei Yuan, Jiaqi Yue, Yitao Tian et al. · 2023 · Cancer Research
  100. Radioresponsive Delivery of Toll-like Receptor 7/8 Agonist for Tumor Radioimmunotherapy Enabled by Core-Cross-Linked Diselenide Nanoparticles
    Yanxian Wu, Jianzhong Qin, Yuan Gu, Gang Zhao, Pei Xu, Subin Lin, Xiaju Cheng, Leshuai W. Zhang, Yangyun Wang, Yong Wang · 2024 · ACS Nano